Palvella Therapeutics, Inc. $PVLA Shares Sold by First Light Asset Management LLC

Posted by Francis Steltz on Sep 10th, 2026

First Light Asset Management LLC lowered its stake in shares of Palvella Therapeutics, Inc. (NASDAQ:PVLA – Free Report) by 21.3% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 771,901 shares of the company’s stock after selling 208,857 shares during the period. Palvella Therapeutics makes up approximately 7.2% of First Light Asset Management LLC’s portfolio, making the stock its 5th biggest holding. First Light Asset Management LLC owned approximately 0.05% of Palvella Therapeutics worth $117,962,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. KBC Group NV purchased a new position in shares of Palvella Therapeutics in the 1st quarter worth $28,000. Northwestern Mutual Wealth Management Co. acquired a new position in Palvella Therapeutics during the second quarter valued at approximately $35,000. Group One Trading LLC increased its holdings in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after purchasing an additional 200 shares in the last quarter. Russell Investments Group Ltd. purchased a new position in Palvella Therapeutics in the third quarter valued at about $36,000. Finally, Archer Investment Corp acquired a new position in Palvella Therapeutics during the 2nd quarter worth approximately $69,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $270.00 price target on shares of Palvella Therapeutics in a research note on Wednesday, July 22nd. Stephens reiterated an “overweight” rating and set a $220.00 target price on shares of Palvella Therapeutics in a research note on Thursday, May 21st. Chardan Capital upgraded shares of Palvella Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. Truist Financial set a $207.00 price objective on shares of Palvella Therapeutics in a research note on Wednesday, August 5th. Finally, Canaccord Genuity Group set a $232.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, August 5th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $209.14.

Read Our Latest Stock Report on PVLA

Palvella Therapeutics Stock Down 0.6%

Shares of PVLA stock opened at $151.34 on Thursday. The stock has a 50-day simple moving average of $148.65 and a 200 day simple moving average of $131.34. Palvella Therapeutics, Inc. has a fifty-two week low of $53.30 and a fifty-two week high of $161.38. The stock has a market capitalization of $2.18 billion, a P/E ratio of -31.33 and a beta of -0.25.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($1.52) EPS for the quarter, missing the consensus estimate of ($1.17) by ($0.35). On average, sell-side analysts anticipate that Palvella Therapeutics, Inc. will post -6.36 earnings per share for the current year.

Insider Activity

In related news, Director Christopher P. Kiritsy sold 313 shares of the firm’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a total transaction of $49,141.00. Following the completion of the sale, the director directly owned 250 shares in the company, valued at approximately $39,250. This trade represents a 55.60% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $152.21, for a total transaction of $654,807.42. Following the completion of the transaction, the chief operating officer owned 2,154 shares in the company, valued at approximately $327,860.34. This trade represents a 66.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 8,917 shares of company stock valued at $1,180,309. Insiders own 17.20% of the company’s stock.

About Palvella Therapeutics

(Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.